For disse patienter var der ingen forskel i incidensen af øvre gastrointestinale bivirkninger, uanset om de fik 150 mg én gang om måneden eller 2, 5 mg daglig.
For these patients, there was no difference in the incidence of upper gastrointestinal adverse events with the 150 mg once monthly regimen compared to the 2.5 mg daily regimen.